Healthcare
Exicure, Inc.(XCUR)
Live Price
Offline$2.89
+2.48% today
1Y Change
-66.92%
Window
Jun 23, 2025 → Jun 17, 2026
- Market Cap
- $20.00M
- Revenue Growth
- -100.0%
- EPS Growth
- +50.3%
- Dividend Yield
- 0.0%
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Exicure, Inc. (XCUR) is a Healthcare stock with a market cap of $20.00M and listed on NASDAQ. The stock last traded around $2.89 and down 66.9% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +50.3%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +50.3%, free cash flow -194.0% with operating margin 0.0% and ROIC -36.1%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines XCUR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at +50.3%, with operating margin around 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XCUR
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XCUR Max Drawdown
-75.73%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for XCUR and SPY.
Company Overview
Exicure, Inc.
NASDAQ Capital Market
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
- Leadership
- Jungsoo Kim
- IPO Date
- May 22, 2018
- Employees
- 7
- Street Address
- 2430 North Halsted Street
- Mailing
- Chicago, IL, 60614
- Region
- Chicago, IL, US
- Reporting Currency
- USD
- Investor Line
- 847 673 1700
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- —
- Price/Book
- 5.4
Growth
- Revenue
- -100.0%
- EPS
- +50.3%
- Free Cash Flow
- -194.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -63.6%
- ROIC
- -36.1%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 1.19
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.